TY - JOUR
T1 - Evidence-Based Pharmacotherapies for Alcohol Use Disorder
T2 - Clinical Pearls
AU - Fairbanks, Jeremiah
AU - Umbreit, Audrey
AU - Kolla, Bhanu Prakash
AU - Karpyak, Victor M.
AU - Schneekloth, Terry D.
AU - Loukianova, Larissa L.
AU - Sinha, Shirshendu
N1 - Publisher Copyright:
© 2020 Mayo Foundation for Medical Education and Research
PY - 2020/9
Y1 - 2020/9
N2 - Pathologic alcohol use affects more than 2 billion people and accounts for nearly 6% of all deaths worldwide. There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate. Of growing interest is the use of anticonvulsants for the treatment of alcohol use disorder, although currently none are FDA approved for this indication. Baclofen, a γ-aminobutyric acid B receptor agonist used for spasticity and pain, received temporary approval for alcohol use disorder in France. Despite effective pharmacotherapies, less than 9% of patients who undergo any form of alcohol use disorder treatment receive pharmacotherapies. Current evidence does not support the use of pharmacogenetic testing for treatment individualization. The objective of this review is to provide knowledge on practice parameters for evidenced-based pharmacologic treatment approaches in patients with alcohol use disorder.
AB - Pathologic alcohol use affects more than 2 billion people and accounts for nearly 6% of all deaths worldwide. There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate. Of growing interest is the use of anticonvulsants for the treatment of alcohol use disorder, although currently none are FDA approved for this indication. Baclofen, a γ-aminobutyric acid B receptor agonist used for spasticity and pain, received temporary approval for alcohol use disorder in France. Despite effective pharmacotherapies, less than 9% of patients who undergo any form of alcohol use disorder treatment receive pharmacotherapies. Current evidence does not support the use of pharmacogenetic testing for treatment individualization. The objective of this review is to provide knowledge on practice parameters for evidenced-based pharmacologic treatment approaches in patients with alcohol use disorder.
UR - http://www.scopus.com/inward/record.url?scp=85084969477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084969477&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2020.01.030
DO - 10.1016/j.mayocp.2020.01.030
M3 - Review article
C2 - 32446635
AN - SCOPUS:85084969477
SN - 0025-6196
VL - 95
SP - 1964
EP - 1977
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 9
ER -